Position: Interim Chair of Pathology
Department: Pathology
Medical School: Tongji Medical College, Huazhong University of Science and Technology, China
Academic Rank: Professor, Chief Physician
Tumor pathological diagnosis and molecular pathology.
Tumor and cholesterol metabolism.
Nano-medicine to anti-tumor proliferation and drug resistance.
Science and Technology Progress Award of Xinjiang Production and Construction Corps, Second Prize, 2020
Science and Technology Progress Award of Xinjiang Production and Construction Corps, Second Prize, 2013
Member, Pathology Teaching Working Committee, Pathology Branch of Chinese Medical Association
Member, Ultramicro and Molecular Pathology Professional Committee of Chinese Research Hospital Association
Vice Chair, Pathology Quality Control Center of Xinjiang Production and Construction Corps
Dr. Zou Hong is committed to tumor pathological diagnosis and molecular diagnosis, and discovered some new immunohistochemical antibody combinations in tumor differential diagnosis.
In addition, she and her team conducted research on the interaction mechanism between tumors and abnormal cholesterol metabolism, especially the regulation and molecular mechanism of HDL receptor SR-B1 gene on the proliferation and invasion of clear cell renal cell carcinoma.
Besides, her team has made progress in the development of nano-drugs to anti colon cancer proliferation and drug resistance.
Yali Hu#，Kunpeng Zhang#， Xingyao Zhu#, Xiuyan Zheng, Chao Wang, Xiao Niu, Teng Jiang, Xinhua Ji, Weilin Zhao, Lijuan Pang, Yan Qi, Feng Li, Li Li, Zhiping Xu, Wenyi Gu* , Hong Zou*. Synergistic Inhibition of Drug-resistant Colon Cancer Growth with PI3K /mTOR Dual Inhibitor BEZ235 and Nano-emulsioned Paclitaxel via reducing multidrug resistance and promoting apoptosis. International Journal of Nanomedicine，2021:16 2173–2186
Hong Zou, Li Li, Ines Garcia Carcedo, Zhi Ping Xu, Michael Monteiro, Wenyi Gu*. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis. International Journal of Nanomedicine, 2016,5(11):1947-58.
Weilin Zhao#, Mei Cui#, Ruiqi Zhang, Xihua Shen, Xin Xiong, Xinhua Ji, Lin Tao, Wei Jia, Lijuan Pang, Zhenzhu Sun, Chun Wang*, Hong Zou*.IFITM1, CD10, SMA, and h-caldesmon as a helpful combination in differential diagnosis between endometrial stromal tumor and cellular leiomyoma. BMC Cancer (2021) 21:1047 https://doi.org/10.1186/s12885-021-08781-w
Xin Xiong#, Fang Liu#, Weilin Zhao, Xinhua Ji, Weigang Chen, Hong Zou*, Feng Li*. Cytomegalovirus infective gastritis in an immunocompetent host misdiagnosed as malignancy on upper gastrointestinal endoscopy: a case report and review of literature. Human Pathology, 2019,(10). DOI: pii:S0046-8177(18)30499-4.
Teng Jiang#, Xiaoli Diao#, Meili Ding, Xiao Niu,Chao Wang,Yan Qi, Wei Jia,Lijuan Pang, Wenhao Hu, Hong Zou*, Feng Li*. SR?B1 and CD10 combined immunoprofile for differential diagnosis of metastatic clear cell renal cell carcinoma and clear cell carcinoma of the ovary. Journal of Molecular Histology. Received: 13 October 2020 / Accepted: 8 February 2021.https://doi.org/10.1007/s10735-021-09963-3.
Kelu Li#, ChaoWang#, Xin Xiong, Hongmei Ma, YanQi, Wenhao Hu, Shuyuan Xiao, Xiaojun Zhou, Lijuan Pang*, Hong Zou*. Small-cell variant renal oncocytoma: case report on its clinicopathological and genetic characteristics and literature review. Gene, 2020,730:144266.
Qi Y# , Huang Y# , Pang L , Gu W , Wang N , Hu J , Cui X , Zhang J , Zhao J , Liu C , Zhang W , Zou H* , Li F* . Prognostic value of the MicroRNA-29 family in multiple human cancers: A meta-analysis and systematic review. Clin Exp Pharmacol Physiol, 2017,44(4):441-454
The study of mechanism on synergistic inhibition of colon cancer cell growth with nanoemulsion loaded paclitaxel and PI3K /mTOR Dual Inhibitor BEZ235. Funding Source: National Natrual Science Fundation of China.
The role of SR-B1 in the biological behavior and hypoxic lipid metabolism of clear cell renal cell carcinoma. Funding Source: National Natrual Science Fundation of China.
Preclinical Key Technology Research of Anti-colon Cancer Nano-paclitaxel and PI3K/mTOR Dual Pathway Inhibitor BEZ235 Compound Preparation. Funding Source: International cooperation project of Xinjiang Production and Construction Corps.
88 Jiefang Road,Shangcheng District Hangzhou,China, 310009
1511 Jianghong Road,Binjiang District Hangzhou,China, 310014
300 Yuanju Road, Shangcheng DIstrict, Hangzhou
456 Qidi Road, Xiaoshan District, Hangzhou, China
1 Xihu Avenue, Shangcheng District, Hangzhou
Zijingang Campus of Zhejiang University, 866 Yuhangtang Road, Xihu District, Hangzhou
Please call +86-571-8971 3988 (8am-5pm, Monday through Friday)
Make an appointment online
The Second Affiliated Hospital
Zhejiang University School of Medicine
88 Jiefang Road, Hangzhou, China
+86-571-8731 5108
iao_sahzu@zju.edu.cn
The Needs of Patients and Customers Come First.
The Second Affiliated Hospital Zhejiang University School of Medicine
All Rights Reserved.
